InSite Vision Inc. (INSV)
Morgan Stanley analyst Eric Hecht repeated a "buy," saying the recent sell-off in the stock is likely due to hostile market conditions for biotech and large distributions of stock from venture capitalists. The fundamentals of the Alameda, Calif., company are intact and most of its products possess little risk in terms of safety and efficacy, he said. With a valuation of just over $50 million and $30 million in cash, he said the